Sign in

NCI CIP-Net

@nci-cipnet.org
8 followers 10 following 66 posts

Official BlueSky account of the NCI Cancer Immunoprevention Network (CIP-Net). www.nci-cipnet.org

PostsRepliesMedia
NCI CIP-Net @nci-cipnet.org · 21/09/2026
📢 Registration is open for the 4th Biennial Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Meeting! 📅 September 28–30, 2026 💻 Virtual & free to attend Register: events.cancer.gov/cadrg/tacpad... #CancerPrevention #CancerResearch #TACPAD #CancerInterception #NCI
events.cancer.gov
cadrg-tacpad (Registration) | Events Registration
RegistrationThank you for your interest in registering for the Translational Advances in Cancer Prevention Agent Development (TACPAD) – 4th Biennial Virtual Meeting. Please use the form below to regis...
000
NCI CIP-Net @nci-cipnet.org · 09/09/2026
Dr. Philip Castle, Director of the NCI Division of Cancer Prevention (DCP), delivered an insightful and inspiring featured seminar on “No Cancer” Research, challenging us to think about what success in cancer research ultimately looks like: preventing cancer before it ever develops.
100
NCI CIP-Net @nci-cipnet.org · 09/09/2026
Dr. Alan Hutson of Roswell Park Comprehensive Cancer Center presented updates on the work of the CIP-Net Data and Resource Coordinating Center (DRCC). As the host of this year’s Annual Meeting, he also shared some fun facts about Buffalo that many attendees may not have known!
100
NCI CIP-Net @nci-cipnet.org · 09/09/2026
Dr. Nicholas Arpaia, Chair of the Community Engagement Working Group, Dr. Anjana Bhardwaj and Dr. Henry Withers, Chair and Co-Chair of the Resource Sharing Working Group, shared updates on the progress and activities of their respective WGs.
100
NCI CIP-Net @nci-cipnet.org · 09/09/2026
Dr. Phillip Castle, Director of the NCI Division of Cancer Prevention, delivered opening remarks to kick off Day 2 of the hashtag#CIPNet Annual Meeting, setting the stage for discussions on advancing cancer immunoprevention.
000
NCI CIP-Net @nci-cipnet.org · 08/09/2026
At the #CIPNet Annual Meeting, the panel “Identifying Risks and Benefits in Cancer Immunoprevention from the Patient Perspective” brought patient advocates and researchers together to discuss how patient experiences can shape research priorities, clinical trial design, and communication.
110
NCI CIP-Net @nci-cipnet.org · 08/09/2026
The CIP-Net Annual Meeting kicked off today at Roswell Park Comprehensive Cancer Center, bringing together 40+ attendees from institutions across the nation! CIP-Net Steering Committee Co-Chair and DRCC Contact PI Dr. Alan Hutson officially opened the meeting.
100
Reposted by NCI CIP-Net
CAP-IT @ncicapit.org · 03/09/2026
New NIH Highlighted Topic: Accelerating Disease Prevention Research by New Approach Methodologies (NAMs) NCI is encouraging applications using human-relevant NAMs to advance precancer biology, cancer prevention, and cancer interception. Learn more: grants.nih.gov/funding/find...
grants.nih.gov
Accelerating Disease Prevention Research by New Approach Methodologies | Grants & Funding
001
NCI CIP-Net @nci-cipnet.org · 03/09/2026
🎙️ CIP-Net Podcast Episode 1 is live! Drs. Bodour Salhia and Robert Samstein discuss the emerging science of cancer immunoprevention and how the immune system could help prevent cancer before it develops. 🎧 Listen now: www.nci-cipnet.org/en/news-podc...
011
NCI CIP-Net @nci-cipnet.org · 01/09/2026
What is cancer immunoprevention and how does it work? The #CIPNet Community Engagement Working Group created this infographic to make the science of cancer immunoprevention more accessible to everyone. 📥 Download it, share it, and help us spread the knowledge! #CancerImmunotherapy #CancerPrevention
What is cancer immunoprevention and how does it work?
The #CIPNet Community Engagement Working Group created this infographic to make the science of cancer immunoprevention more accessible to everyone.Download it, share it, and help us spread the knowledge!
021
NCI CIP-Net @nci-cipnet.org · 25/08/2026
This is why we have invested so much time and effort in promoting resource sharing within our network—not only to reduce waste, but also to share resources, including antibodies, together with the collective validation experience and knowledge of our research community.
000
NCI CIP-Net @nci-cipnet.org · 25/08/2026
CIP-Net has compiled a curated list of NCI/NIH shared resources, providing cancer researchers with a convenient, one-stop place to find useful research resources. nci-cipnet.org/en/resources...
nci-cipnet.org
CIP-Net
000
NCI CIP-Net @nci-cipnet.org · 24/08/2026
At today’s #CIPNetSCMeeting, SC co-chair Dr. Alan Hutson provided an overview of network activities. Dr. Anirban Maitra introduced the NCI TBEL Consortium and highlighted its research progress in pancreatic cancer. Dr. Shawn Demehri shared progress from his UH3 project.
000
NCI CIP-Net @nci-cipnet.org · 21/08/2026
Can we harness the immune system to stop cancer before it becomes invasive? This JITC review explores advances, opportunities & challenges in #CancerImmunoprevention and #ImmuneInterception. It also highlights #CIPNet and its role in advancing this emerging field. 🔗 jitc.bmj.com/content/12/3...
jitc.bmj.com
000
NCI CIP-Net @nci-cipnet.org · 18/08/2026
New NIH Highlighted Topic: Immune Mechanisms for Disease Prevention grants.nih.gov/funding/find...
grants.nih.gov
Immune Mechanisms for Disease Prevention | Grants & Funding
000
NCI CIP-Net @nci-cipnet.org · 12/08/2026
Worth revisiting: a 2020 perspective published in Cancer Prevention Research, exploring the challenges and potential opportunities for immune checkpoint inhibitors in cancer immunoprevention. The concepts remain highly relevant to #CIPNet’s mission today. 🔗 doi.org/10.1158/1940...
doi.org
Cancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint Inhibitors
Abstract. Cancer immunoprevention is achieved through promoting antitumor immune surveillance to block tumor formation and progression. Following the success of prophylactic vaccines against human pap...
000
NCI CIP-Net @nci-cipnet.org · 31/07/2026
Published in Nature Protocols, this new tutorial from NIH researchers provides a practical roadmap for integrating frontier large language models (LLMs) into healthcare. www.nature.com/articles/s41...
nature.com
Tutorial: guidance on the use of large language models for medical research - Nature Protocols
An entry-level guide for understanding how to choose large language models for medical research applications, customize the prompts and fine-tune the models’ performance.
000
NCI CIP-Net @nci-cipnet.org · 15/07/2026
Register now for the upcoming NCI Office of Data Sharing Seminar Series on July 29, 2026! Join Dr. Julian Hong of UCSF as he presents "Generalizable Multimodal AI Approaches to Advance Cancer Care Delivery." Register here: events.cancer.gov/ods/webinar/...
events.cancer.gov
ODS Webinar Series (Upcoming Webinars) | Events Registration
Upcoming Webinars
002
Reposted by NCI CIP-Net
CAP-IT @ncicapit.org · 15/07/2026
📢 Registration deadline extended! Join the 2026 #NCIDataJamboree (Nov. 16–18) using public cancer datasets to advance cancer research. Submit your project and register by July 27, 2026. events.cancer.gov/nci/datajamb...
events.cancer.gov
NCI Data Jamboree (Registration) | Events Registration
RegistrationPlease ensure you also submit information under "Project Submission" as a Project Lead or Project Seeker.
002
Reposted by NCI CIP-Net
American Association for Cancer Research (AACR) @theaacr.bsky.social · 06/07/2026
The latest development in lymphoma research took center stage at the AACR Special Conference on Advances in Malignant Lymphoma. Explore highlights from the meeting on the #AACRBlog: www.aacr.org/blog/2026/07... #AACRlymphoma26
041
NCI CIP-Net @nci-cipnet.org · 29/06/2026
Congratulations to Dr. Haval Shirwan on being named the recipient of the 2026 Basic Science Established Investigator Award by the American Society of Transplantation (AST)! www.myast.org/blog/ast-con...
myast.org
AST Congratulates 2026 Award Recipients
Make a difference in the field of transplantation by donating to support our cause.
000
NCI CIP-Net @nci-cipnet.org · 10/06/2026
What if bacteria could be programmed to find tumors and deliver cancer therapies directly where they're needed? A new Nature Cancer Perspective by Noah Chen, Zaofeng Yang, and Nicholas Arpaia explores the promise of engineered bacteria as living therapeutics: rdcu.be/fmtyo
rdcu.be
Bacterial engineering for cancer therapy
Nature Cancer - In this Perspective, Arpaia and colleagues provide an overview of bacteria-based cancer therapies, discussing the potential of engineered bacteria as living drug delivery systems as...
000
NCI CIP-Net @nci-cipnet.org · 03/06/2026
Join the NCI Division of Cancer Prevention Immunology Interest Group for a special seminar presentation on Wednesday June 10 at 1pm ET. We will hear from Dr. Nicholas Arpaia: "Programmable Probiotics for Personalized Cancer Immunoprevention and Immunotherapy." Register today: go.nih.gov/QysclHR
000
NCI CIP-Net @nci-cipnet.org · 21/05/2026
Register now for the NCI Division of Cancer Prevention Early Career Scientist Spotlight Research Seminar Series. events.cancer.gov/dcp/early-ca...
000
NCI CIP-Net @nci-cipnet.org · 05/05/2026
A curated list of NIH/NCI shared resources is now available on our web portal. Check it out: nci-cipnet.org/en/resources...
000
NCI CIP-Net @nci-cipnet.org · 04/05/2026
Great kickoff for the CIP-Net Resource Sharing WG today! 🚀 Many thanks to WG Chairs Drs. Anjana Bhardwaj/Henry Withers for leading a thoughtful discussion on building a collaborative framework for resource sharing .And thank you to all members for the active participation & valuable input.
000
NCI CIP-Net @nci-cipnet.org · 28/04/2026
🥦 New #CIPNetPublication highlights the power of diet in cancer interception pubmed.ncbi.nlm.nih.gov/41342739/ #CancerPrevention #Immunoprevention #Microbiome #MultipleMyeloma
pubmed.ncbi.nlm.nih.gov
Checking your browser - reCAPTCHA
000
NCI CIP-Net @nci-cipnet.org · 27/04/2026
At today’s #CIPNetSCMeeting, Dr. Haval Shirwan delivered opening remarks, followed by a network update from Dr. Alan Hutson. Dr. Sean Hanlon of NCI presented on #HTAN. Dr. Tal Danino shared a progress report on engineered probiotic bacteria for colorectal cancer #immunoprevention and interception.
000
NCI CIP-Net @nci-cipnet.org · 24/04/2026
CIP-Net Project Spotlight: Developing a novel CD137 agonist (SA-4-1BBL) to train the immune system for cancer #immunoprevention. Led by Haval Shirwan & Esma Yolcu, this project explores how immune activation can prevent tumor development in high-risk populations. www.nci-cipnet.org/en/members/u...
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
000
NCI CIP-Net @nci-cipnet.org · 22/04/2026
Apply to access the scientific capabilities and resources of the National Cancer Institute (NCI) with the goal of moving promising cancer preventive agents into clinical testing. prevention.cancer.gov/research-are...
prevention.cancer.gov
https://prevention.cancer.gov
General InstructionsPlease apply using the PREVENT Application System.Next application deadline is May 4, 2026.Required DocumentsPREVENT Concept ApplicationFor
000
NCI CIP-Net @nci-cipnet.org · 03/04/2026
The Cancer Immunoprevention Network, established by the National Cancer Institute, advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions. More info: nci-cipnet.org
nci-cipnet.org
CIP-Net
000
NCI CIP-Net @nci-cipnet.org · 24/03/2026
Join us today at 11 AM ET for the Early Career Scientist Spotlight Research Seminar Series, hosted by the NCI Division of Cancer Prevention. events.cancer.gov/dcp/early-ca...
events.cancer.gov
DCP Early Career Scientist Spotlight Research Seminar Series (Upcoming Research Talks) | Events Registration
Upcoming Research Talks
000
NCI CIP-Net @nci-cipnet.org · 18/03/2026
🧬 CIP-Net Project Spotlight: What drives the transition from MGUS to multiple myeloma? This project led by Drs. Madhav Dhodapkar, Richard Flavell, & Noah Palm explores how gut microbes may act as antigenic triggers for B cells. nci-cipnet.org/en/members/u...
nci-cipnet.org
CIP-Net
001
NCI CIP-Net @nci-cipnet.org · 06/03/2026
Register now for the NCI Division of Cancer Prevention Early Career Scientist Spotlight Research Seminar Series. events.cancer.gov/dcp/early-ca...
000
NCI CIP-Net @nci-cipnet.org · 06/03/2026
Register now for the @theNCI Division of Cancer Prevention Early Career Scientist Spotlight Research Seminar Series. events.cancer.gov/dcp/early-ca...
000
NCI CIP-Net @nci-cipnet.org · 04/03/2026
🧬CIP-Net Project Spotlight: Led by Drs. Peter Leif Bergsagel and Marta Chesi of Mayo Clinic, this project investigates how inflammatory cues within the bone marrow microenvironment promote malignant progression during SMM. Learn more👉https://nci-cipnet.org/en/members/ug3ca290468/
000
NCI CIP-Net @nci-cipnet.org · 24/02/2026
Only a few spots remaining! This is a great opportunity for early stage investigators to showcase their work to a broad scientific community. prevention.cancer.gov/funding-and-...
prevention.cancer.gov
Early Career Scientist Opportunity
2026 Annual Call for Nominations to Highlight Early Career Scientists Conducting Research within the Mission of the NCI Division of Cancer PreventionPurpose
001
NCI CIP-Net @nci-cipnet.org · 23/02/2026
At today’s #CIPNetSCMeeting, Dr. Haval Shirwan and Dr. Preethi Gunaratne announced the formation of a White Paper Task Force and invited additional interested participants to join. Dr. Alan Hutson shared DRCC updates. Drs. Leif Bergsagel and Marta Chesi presented progress on their UG3 project.
000
NCI CIP-Net @nci-cipnet.org · 20/02/2026
🧬CIP-Net Project Spotlight: Immune determinants modulating cancer development in #LynchSyndrome This project will define the shared frameshift neoantigens and T cell features that restrain progression from precancerous polyps to CRC. 👉https://nci-cipnet.org/en/members/ug3ca290517/
000
NCI CIP-Net @nci-cipnet.org · 18/02/2026
🧬 CIP-Net Project Spotlight - Investigating novel targets for topical immunoprevention of keratinocytic skin cancer. Led by Drs. Sally Dickinson and Curiel Clara, this project explores how UV-induced immune checkpoint signals drive early skin carcinogenesis. www.nci-cipnet.org/en/members/u...
000
NCI CIP-Net @nci-cipnet.org · 10/02/2026
New #CIPNetPublication: Drs. Haval Shirwan, Esma Yolcu and team dissect how SA-4-1BBL, a CD137 agonist, drives balanced and durable immune activation to prevent cancer, using advanced bioinformatics and transcriptomic analyses. The work is published in Biomolecules MDPI www.mdpi.com/2218-273X/16...
mdpi.com
000
NCI CIP-Net @nci-cipnet.org · 10/02/2026
🧬CIP-Net Project Spotlight UG3CA290300, led by Dr. Shadmehr Demehri, is investigating how the immune system can protect normal breast tissue and intercept cancer before it starts in people with inherited BRCA mutations 👉Learn more: www.nci-cipnet.org/en/members/u...
000
NCI CIP-Net @nci-cipnet.org · 09/02/2026
🧬 CIP-Net Project Spotlight UG3CA290454 is developing a preventive cancer vaccine for people with inherited BRCA1/2 mutations, using chimeric RNA-derived neoantigens to stop breast cancer before it forms. 👉Learn more on the CIP-Net website: www.nci-cipnet.org/en/members/u...
nci-cipnet.org
CIP-Net
022
NCI CIP-Net @nci-cipnet.org · 23/01/2026
At today’s NCI Computational Oncology Working Group meeting, Dr. Roland Dunbrack of Fox Chase Cancer Center presented his work on structural bioinformatics and AlphaFold modeling of the human kinome and its interactions.
020
NCI CIP-Net @nci-cipnet.org · 22/12/2025
#CIPNetPublication in Nature Cancer by Dr. Madhav Dhodapkar: The MyCheckpoint randomized trial reports durable clinical responses in multiple myeloma following TIGIT or LAG3 immune checkpoint blockade, with distinct pathway-specific immune correlates for each arm. pubmed.ncbi.nlm.nih.gov/39187595/
pubmed.ncbi.nlm.nih.gov
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial - PubMed
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was we …
000
NCI CIP-Net @nci-cipnet.org · 15/12/2025
#CIPNetSCMeeting
000